Who is sponsoring NCT05060770?

NCT05060770 is sponsored by Central Hospital, Nancy, France.

What drugs are being tested in NCT05060770?

Interventions in NCT05060770: transcriptomic analysis.

What condition does NCT05060770 study?

NCT05060770 studies Colorectal Cancer, Genetics of.

Is NCT05060770 still recruiting?

NCT05060770 is currently completed. Last updated 7 October 2021.

Last reviewed 2021-10-07 · How we verify

NCT05060770

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Transcriptomic Study of IBD-associated Colorectal Cancer

Completed Last updated 7 October 2021

What this trial tests

trial testing transcriptomic analysis in Colorectal Cancer, Genetics of in 26 participants. Completed in 1 January 2021.

Timeline

1 January 2010

Primary endpoint
1 January 2021

1 January 2021

Quick facts

Lead sponsor	Central Hospital, Nancy, France
Status	Completed
Study type	OBSERVATIONAL
Enrollment	26
Start date	1 January 2010
Primary completion	1 January 2021
Estimated completion	1 January 2021

Drugs / interventions tested

transcriptomic analysis — full drug profile →

Conditions studied

Colorectal Cancer, Genetics of — all drugs for Colorectal Cancer, Genetics of →

Sponsor

Central Hospital, Nancy, France

Who can join

Adults 18 to 100, any sex, with Colorectal Cancer, Genetics of. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Chronic inflammatory bowel disease (IBD) is associated with an increased risk of colorectal cancer (CRC) in historical cohorts. The pathways of oncogenesis of these CRCs, which are very different clinically from de novo CRCs, are currently unknown. The aim of our work is to identify specific molecular signatures of CRC occurring in the setting of IBD.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of transcriptomic analysis

Trials testing the same drug.

NCT05524311 — Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT) · Phase 2 · completed

Other recruiting trials for Colorectal Cancer, Genetics of

Currently open trials in the same condition.

NCT04157322 — Plasma 5hmC Signatures as a Marker of Colorectal / Appendiceal Peritoneal Metastasis · active not recruiting

Other Central Hospital, Nancy, France trials

Trials by the same sponsor.

NCT06452290 — PET Biomarker Study for Antidepressant Response Prediction in Major Depressive Disorder · NA · not yet recruiting
NCT07518498 — Hypnosis During Mechanical Ventilation Weaning · NA · not yet recruiting
NCT07471334 — Prospective Study of Postictal Psychotic Symptoms Occuring After Video-EEG Monitoring in Focal Epilepsies · NA · not yet recruiting
NCT07414667 — Primary Sjögren's Syndrome: Impact of Quantitative Anti-Ro52 Antibody Analysis on Patient Prognosis and Stratification ( · not yet recruiting
NCT07415759 — Imaging of Electrical Properties by MRI: Investigation of Age-Related Changes · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05060770 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Central Hospital, Nancy, France
Last refreshed: 7 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05060770.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing